Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics

Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.

The word Cancer hidden in a strand of DNA

Exact Sciences Corp. has entered into an agreement to buy Thrive Earlier Detection Corp. for cash and stock consideration of up to $2.15 billion in a move to strengthen its position in the emerging multi-cancer screening market.

Exact, the company behind the Cologuard stool-based colorectal cancer test has been upfront about its aspirations to be leader in...

More from Deals

More from Business